{"article_title": "Senate to conduct investigation into Rx drug pricing", "article_keywords": ["senate", "turing", "price", "rx", "drug", "pharmaceuticals", "investigation", "pricing", "committee", "conduct", "prices", "public", "recent"], "article_url": "http://drugtopics.modernmedicine.com/drug-topics/news/senate-conduct-investigation-rx-drug-pricing", "article_text": "The U.S. Senate will conduct a bipartisan investigation into pharmaceutical drug prices following recent public and political outrage over drastic price increases for certain drugs.\n\nThe Senate Special Committee on Aging has scheduled a hearing for December 9, 2015. The committee has sent letters to Valeant Pharmaceuticals, Turing Pharmaceuticals, Retrophin, and Rodelis Therapeutics requesting specific information.\n\nEditor\u2019s Choice: Rising Rx prices front and center in presidential campaign\n\n\u201cSome of the recent actions we\u2019ve seen in the pharmaceutical industry\u2014with corporate acquisitions followed by dramatic increases in the prices of pre-existing drugs\u2014have looked like little more than price gouging,\u201d U.S. Senator Claire McCaskill, (D-Mo.) stated in a release.\n\n\u201cWe need to get to the bottom of why we\u2019re seeing huge spikes in drug prices that seemingly have no relationship to research and development costs. I\u2019m proud to help lead this bipartisan investigation so that we can find some answers the public wants and deserves,\u201d he added.\n\nMcCaskill and U.S. Senator Susan Collins (R-Maine), another member of Senate Special Committee on Aging, said the hearing would focus on drugs that have recently had significant price hikes.\n\n\u201cWe seek your cooperation with this investigation so that the Committee may better understand drug pricing and related regulatory and public policy concerns,\u201d the letter to Turing Pharmaceuticals CEO Martin Shkreli stated. \u201cIn particular, the Committee wishes to learn more about Turing Pharmaceuticals\u2019 recent acquisition of the rights to sell Daraprim, a drug used to treat and prevent infections, from Impax Laboratories and Turing\u2019s subsequent decision to increase the price of Daraprim from $13.50 to $750 [per tablet].\u201d", "article_metadata": {"DC.description": "The U.S. Senate will conduct a bipartisan investigation into pharmaceutical drug prices following recent public and political outrage over drastic price increases for certain drugs.", "Description": "The U.S. Senate will conduct a bipartisan investigation into pharmaceutical drug prices following recent public and political outrage over drastic price increases for certain drugs.", "og": {"url": "http://drugtopics.modernmedicine.com/drug-topics/news/senate-conduct-investigation-rx-drug-pricing", "site_name": "Drug Topics", "description": "The U.S. Senate will conduct a bipartisan investigation into pharmaceutical drug prices following recent public and political outrage over drastic price increases for certain drugs.\n\n\tThe Senate Spe", "title": "Senate to conduct investigation into Rx drug pricing"}, "DC.identifier": "http://drugtopics.modernmedicine.com/node/413927", "robots": "INDEX,FOLLOW", "DC.publisher": "Advanstar Communications Inc", "DC.date": "2015-11-13", "last-modified": "Sat, 14 November 2015 00:11:26 GMT", "DC.creator": "Mark Lowery, Content Editor", "DC.source": "Drug Topics E-News", "google-site-verification": "WZJsn2WE41IwLNlFfGQmdu6DHXhiwsg_s5ZCzVREpaM", "DC.subject": "Chains & Business, Claire McCaskill, Legislative, prescription drug prices, Rx Care, Susan Collins, The Latest, u.S. senate", "emsContentType": "Senate to conduct investigation into Rx drug pricing", "DC.title": "Senate to conduct investigation into Rx drug pricing"}, "article_summary": "The U.S. Senate will conduct a bipartisan investigation into pharmaceutical drug prices following recent public and political outrage over drastic price increases for certain drugs.\nThe committee has sent letters to Valeant Pharmaceuticals, Turing Pharmaceuticals, Retrophin, and Rodelis Therapeutics requesting specific information.\n\u201cWe need to get to the bottom of why we\u2019re seeing huge spikes in drug prices that seemingly have no relationship to research and development costs.\n\u201cWe seek your cooperation with this investigation so that the Committee may better understand drug pricing and related regulatory and public policy concerns,\u201d the letter to Turing Pharmaceuticals CEO Martin Shkreli stated.\nThe Senate Special Committee on Aging has scheduled a hearing for December 9, 2015."}